Genematrix

본문 바로가기
ENG
Home  >  Technology  >  New Therapeutics Development
NEW THERAPEUTICS DEVELOPMENT

Original vaccine development technology

We are developing effective next-generation vaccines for the prevention and treatment of various infectious diseases and cancers based on unique original technologies such as our high-efficiency viral vector vaccine platform, built-in immunity enhancement technology, PREFER (Protein REFolding EnhanceR) technology, AI-based antigen remodeling technology, T cell immunity promotion technology, and cell/virus culture/purification technology.
We are also strengthening our development portfolio not only through our own capabilities, but also through active C&D (Connect & Development) with domestic and overseas innovative companies, and through continuous cooperation and joint research with innovative companies, we are searching, deriving, evaluating, and pursuing clinical/non-clinical development of new candidate substances.

1) Chimeric Adenovirus Vector Platform (Chim-Ad)

The chimeric adenovirus vector platform (Chim-Ad) fusers human adenovirus serotype 5 (Ad5) and adenovirus serotype (Rare type) rarely found in humans. It is a proprietary adenovirus vector source technology that improves the problem of pre-existing immunity in the existing Ad5 vector-based platform and improves vaccine productivity and immune induction capability. We are developing effective vaccine candidates based on Chim-Ad, and we are using the platform to develop premium vaccines against various new infectious diseases.

  • High immunogenicity

    • By modifying the major structural proteins of adenovirus recognized by neutralizing antibodies, pre-existing immunity against Ad5 is avoided and vaccine immunity effectiveness is improved.
  • High level of cellular immune response

    • Our Chim-Ad vector has strong cellular immunity inducing ability, including the gene sequence of Ad5, which binds to CD4+ and CD8+ T cell receptors as an epitope.
  • Heterologous prime-boost effect

    • Through heterologous prime-boost immunization using the Chim-Ad vector comprising different serotypes, a synergestic effect is produced by minimizing vector immunity and maximizing antigen immunity.
  • Vaccine cost efficiency

    • Vaccine productivity is enhanced by improving the infection ability of Adenovirus producer cell line through changes in the structural protein of adenovirus that binds to the receptors of the host cell.
  • ← Scroll left and right →

2) Built-in immunity enhancement technology

An adjuvant is used to induce quick and powerful immune response to vaccine antigens and to prolong the duration of immunity. Aluminum salts currently used in most vaccines have are excellent for inducing humoral immunity to form antibodies against antigens, but are disadvantageous for not inducing a cellular immune response. Therefore, various adjuvants are being developed to overcome this limitation.
We are utilizing genetic adjuvant technology that fuses ligands, which activate the immune system by binding to the toll-like receptors (TLR) of antigen presenting cells, with the vaccine antigens at the gene level to develop high-efficiency vaccines

  • TLR Ligand
    TLR 1 Tripalmitoyl-cysteine lipopeptides
    TLR 2 Lipopeptides, beta-glucan, glycolipids
    TLR 3 Double-stranded RNA
    TLR 4 Lipopolsaccharide
    TLR 5 Flagellin
    TLR 6 Dipalmitoyl-cysteine lipopeptides
    TLR 7 Single-stranded RNA
    TLR 8 Single-stranded RNA
    TLR 9 Bacterial DNA

3) Protein REFolding EnhanceR Technology (PREFER)

If the recombinant protein produced in E. coli or yeast is converted into an insoluble inclusion body, it loses its biological activity and medical utility. Protein REFolding EnhanceR (PREFER), our protein activity restoration technology, is a technology that effectively restores the original medical activity by increasing the water solubility of recombinant proteins produced as insoluble inclusion bodies. This enables both mass production and effectiveness of medical protein materials at the same time.
We use our original PREFER technology, one of our core manufacturing technologies, for mass production of recombinant proteins in order to explore the efficacy of vaccine candidates and to mass-produce such candidates.

  • Securing Biological Effectiveness

    • PREFER technology solubilizes recombinant protein in the form of insoluble inclusion bodies and restores it to a more stable and water-soluble structure, thereby securing the original biological effectiveness.
  • Mass Production

    • PREFER technology produces a high yield of recombinant protein by minimizing the amount of time and various processes normally required for restoring protein activity by easily searching for refolding conditions, and it has advantages in mass production system applications.
  • Cost Reduction

    • In general refolding technology, expensive special reagents are used, increasing production costs. PREFER technology enables substantial cost savings on an industrial production scale as it restores protein activity with high efficiency using the smallest amount of commonly used reagents.

← Scroll left and right →

  • Solubilization

  • PREFER
    (Protein
    REFolding
    EnhanceR)

4) AI-based Antigen Remodeling Technology

AI technology is aiding researchers and medical staff in the search for vaccine candidates, and designing and conducting clinical trials based on a vast library of immunity-related data. In particular, in addition to immuno-informatics software, AI-based modeling technology contributes to the selection of the best vaccine candidates by analyzing the three-dimensional structure of proteins faster and more efficiently and predicting the stability and efficacy of recombinant antigens. When viral or tumor-derived proteins with inherent risks are used as vaccine antigens, loss-of-function mutation should be induced for safety. At this time, due to the induced mutations, the distribution of antigenic peptides presented in linear and stereoscopic epitopes and major histocompatibility complexes (MHC) may differ from that of the wild-type antigens. Since this can lead to problems such as decreased immunogenicity and reduced stability of the vaccine antigen, optimization of the antigen sequence through physicochemical characterization of the protein is essential.
We design recombinant antigens based on immuno-informatics software and protein engineering technology and use AI-based antigen remodeling technology to perform structural analysis of vaccine candidates quickly and efficiently, and we conduct efficacy evaluation and clinical development for finally derived vaccine candidates.

← Scroll left and right →

  • Efficacy and Saftey Test
    Clinical Study

회원로그인

회원가입